PROCESS NOW CLOSED.
Immediate Call for Applications
The Vall d´Hebron Institute of Oncology´s (VHIO) newly established Prostate Cancer Translational Research Group, led by Joaquin Mateo, is currently seeking to appoint a Scientific Laboratory Manager. The successful candidate will form an integral part of the scientific team and will support the execution of the translational research program of the group, focused on drug development and the study of correlative biomarkers in advanced prostate cancer.
Our new group will include 4-5 biomedical scientists by Q3-4 2018 and will work in close collaboration with the GU Tumours Group of medical oncologists at VHIO towards the planning and development of precision medicine clinical trials in prostate cancer.
The main objective of the successful candidate will be to combine managerial skills and knowledge of safety and lab procedures to ensure that the laboratory operates smoothly.
The appointed individual will firstly be involved in the setting up of the new laboratory (located on the 4th floor of VHIO´s CELLEX building), including planning and execution of the equipment plan. It is expected that, during the first stages of the execution of the research plan, the candidate will develop tasks as a senior laboratory technician, coordinating the successful optimization of a range of research assays including cell line, DNA, RNA and protein-based work. As new laboratory technicians join the group, it is expected that he/she will focus on laboratory management tasks, although some time could be reserved for hands-on wet laboratory work in line with the successful candidate´s expertise and interests.
Laboratory management tasks include (but are not limited to) maintenance of laboratory equipment performance by establishing quality standards; developing operations, quality, and troubleshooting procedures; ensuring staff compliance and line-managing laboratory technicians; certifying instrument performance; arranging equipment replacement, service, and repair.
The selected candidate will also be key in developing standard operation procedures (SOPs) for the laboratory in accordance with safety and regulatory requirements as well as developing a Lab Safety plan.
An organized, motivated, team-oriented individual with previous experience in a translational research laboratory, ideally with prior experience in cancer research.
Prior involvement in the setting up of equipment and procedures in a new laboratory will be highly valued. The candidate is expected to be able to communicate in English, even if it is not his/her first language.
The ideal candidate should be familiar with:
- Working with human tissue and human genomic material.
- Processing samples for clinical trials.
- Regulatory requirements specifically for laboratories working in clinical trials.
- Background in clinical research methodology and biostatistics would be positively considered.
Review of applications will commence immediately; interviews will be arranged with short-listed candidates.
The candidate should be available to join the group no later than January 2018, although exceptions can be made according to personal circumstances of the candidate, to be discussed at the interview.
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), created by José Baselga in 2007, has established itself as a comprehensive cancer centre of proven excellence internationally. It is thanks to Josep´s directorship and VHIO´s optimal organisational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO´s pioneering model and programmes, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumour types.
VHIO´s translation toward precision oncology: http://www.vhio.net